Peter Greenleaf

Peter Greenleaf

Mr. Greenleaf has spent over two decades in senior leadership roles at leading biopharmaceutical companies and currently serves as Chief Executive Officer and Director of Cerecor Inc., a pediatric commercial organization and leading developer of orphan neurological therapies, as well as Chairman of the Board of BioDelivery Sciences, a specialty pharmaceutical company focused on pain management and addictive medicine.

Previously Mr. Greenleaf was Chief Executive Officer and Chairman of Sucampo Pharmaceuticals, which, under his leadership, was sold to Mallinckrodt Pharmaceuticals in February 2018 for $1.2 billion.  Prior to this, Mr. Greenleaf established himself as a key strategy and business development leader within leading organizations such as Histogenics, MedImmune, Boehringher Mannheim (Roche) and Centocor Biotech (Janssen / JNJ). He also served as President of MedImmune Ventures where he led the activities of AstraZeneca’s wholly-owned venture capital fund.  Mr. Greenleaf has served on the governing boards of several industry organizations (e.g., PhRMA, BIO) and currently chairs the Maryland Venture Fund Authority which seeks to promote venture capital investment in the state.